VC-backed Unity Biotechnology goes public
Brisbane, California-based Unity Biotechnology Inc, a developer of treatments that prevent, halt, or reverse numerous diseases of aging, has raised $85 million for its IPO after pricing its 5 million shares at $17 per share. The stock began trading May 3, 2018 on the NASDAQ under the ticker symbol "UBX." Goldman Sachs, Morgan Stanley and Citigroup are serving as the underwriters. Unity's pre-IPO backers include EcoR1 Capital Fund, 6 Dimensions Capital, Altitude Life Science Ventures, Fidelity Management & Research Company, Baillie Gifford, Partner Fund Management, Pivotal Alpha Limited, Invus Opportunities, ARCH Venture Partners, Venrock, Founders Fund and the Longevity Fund.
3 May 2018•2 mins read
